PreprintCited by 478Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Research Studies

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Open access

Politi, Katerina, Zakowski, Maureen F., Fan, Pang-Dian, Schonfeld, Emily A., Pao, William, Varmus, Harold E.·2006·Genes & Development

DOI 10.1101/gad.1417406

Open this paper in CoChat — free account Open PDF

Abstract

Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor ( EGFR ) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. Nearly 90% of the EGFR mutations are either short, in-frame deletions in exon 19 or point mutations that result in substitution of arginine for leucine at amino acid 858 (L858R). To study further the role of these mutations in the initiation and maintenance of lung cancer, we have developed transgenic mice that express an exon 19 deletion mutant ( EGFR Δ L747–S752 ) or the L858R mutant ( EGFR L858R ) in type II pneumocytes under the control of doxycycline. Expression of either EGFR mutant leads to the development of lung adenocarcinomas. Two weeks after induction with doxycycline, mice that express the EGFR L858R allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas. In contrast, mice expressing EGFR Δ L747–S752 develop multifocal tumors embedded in normal lung parenchyma with a longer latency. With mice carrying either EGFR allele, withdrawal of doxycycline (to reduce expression of the transgene) or treatment with erlotinib (to inhibit kinase activity) causes rapid tumor regression, as assessed by magnetic resonance imaging and histopathology, demonstrating that mutant EGFR is required for tumor maintenance. These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.1417406

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citation
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer
Kim, C. F. B., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., Crowley, D. G., Bronson, R. T., & Jacks, T. (2005) · Cell · doi:10.1016/j.cell.2005.03.032 · Cited by 2,229
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

Flagged first, then by citations

Show all 50 references

Sorted by citations

Items 101–200 of 476

Lineage-specific intolerance to oncogenic drivers restricts histological transformation
Gardner, E. E., Earlie, E. M., Li, K., Thomas, J., Hubisz, M. J., Stein, B. D., Zhang, C., Cantley, L. C., Laughney, A. M., & VARMUS, H. E. (2024) · Science · doi:10.1126/science.adj1415 · Cited by 116
Self-citation
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
Unni, A. M., Harbourne, B., Oh, M. H., Wild, S. A., Ferrarone, J. R., Lockwood, W. W., & VARMUS, H. E. (2018) · eLife · doi:10.7554/elife.33718 · Cited by 111
Self-citation
Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS
Guha, U., Chaerkady, R., Marimuthu, A., Patterson, A., Kashyap, M. K., Gowda, H., Sato, M., Bader, J. S., Lash, A., Minna, J. D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806158105 · Cited by 114
Self-citation
EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR‐targeting tyrosine kinase inhibitors
Takeuchi, K., & Ito, F. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07450.x · Cited by 109
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
Caswell, D. R., Gui, P., Mayekar, M. K., Law, E. K., Pich, O., Bailey, C., Boumelha, J., Kerr, D. L., Blakely, C. M., Manabe, T., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01592-8 · Cited by 114
Predictive in vivo animal models and translation to clinical trials
Cook, N., Jodrell, D. I., & Tuveson, D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.02.003 · Cited by 105
Twist1 Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant Kras-Induced Lung Tumorigenesis
Tran, P. T., Shroff, E. H., Burns, T. F., Thiyagarajan, S., Das, S., Zabuawala, T., Chen, J., Cho, Y., Luong, R. H., Tamayo, P., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002650 · Cited by 108
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98
Rapamycin Prevents Transforming Growth Factor-α–Induced Pulmonary Fibrosis
Korfhagen, T. R., Cras, T. D. L., Davidson, C. R., Schmidt, S., Ikegami, M., Whitsett, J. A., & Hardie, W. D. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0377oc · Cited by 99
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
Uramoto, H., & Mitsudomi, T. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603665 · Cited by 97
Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor
Dechant, M., Beyer, T. D., Schneider‐Merck, T., Weisner, W., Peipp, M., van de Winkel, J. G. J., & Valerius, T. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2936 · Cited by 95
Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome P 450 Reductase-Null Mice
Weng, Y., Fang, C., Turesky, R. J., Behr, M. J., Kaminsky, L. S., & Ding, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1006 · Cited by 93
Epithelial Mesenchymal Transition in Aggressive Lung Cancers
Mittal, V. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_3 · Cited by 93
Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis
Smith, G. D., Chadwick, B. E., Willmore‐Payne, C., & Bentz, J. S. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.051425 · Cited by 90
EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-α-induced pulmonary fibrosis
Hardie, W. D., Davidson, C. R., Ikegami, M., Leikauf, G. D., Cras, T. D. L., Prestridge, A. L., Whitsett, J. A., & Korfhagen, T. R. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00020.2008 · Cited by 89
The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer
Toyooka, S., Matsuo, K., Shigematsu, H., Kosaka, T., Tokumo, M., Yatabe, Y., Ichihara, S., Inukai, M., Suehisa, H., Soh, J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0216 · Cited by 89
ICRP Publication 131: Stem Cell Biology with Respect to Carcinogenesis Aspects of Radiological Protection
Niwa, O., Barcellos‐Hoff, M. H., Globus, R. K., Harrison, J. D., Hendry, J. H., Jacob, P., Martin, M. T., Seed, T. M., Shay, J. W., Story, M. D., et al. (2015) · Annals of the ICRP · doi:10.1177/0146645315595585 · Cited by 91
Signal Transducer and Activator of Transcription 3 (Stat3C) Promotes Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Lung Tumorigenesis
Wu, L., Du, H., Li, Y., Qu, P., & Yan, C. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.028 · Cited by 89
Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas
Tran, P. T., Fan, A. C., Bendapudi, P. K., Koh, S., Komatsubara, K. M., Chen, J., Horng, G., Bellovin, D. I., Giuriato, S., Wang, C. S., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002125 · Cited by 87
Lung Stem and Progenitor Cells in Tissue Homeostasis and Disease
Leeman, K. T., Brainson, C. F., & Kim, C. F. (2014) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-416022-4.00008-1 · Cited by 89
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response
Sangodkar, J., Dhawan, N. S., Melville, H., Singh, V. J., Yuan, E., Rana, H. Q., Izadmehr, S., Farrington, C. C., Mazhar, S., Katz, S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62058 · Cited by 86
Self-citation
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
Politi, K. A., Fan, P., Shen, R., Zakowski, M. F., & VARMUS, H. E. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.003681 · Cited by 86
Self-citation
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas
Zhou, Y., Rideout, W. M., Zi, T., Bressel, A., Reddypalli, S., Rancourt, R. C., Woo, J.-K., Horner, J. W., Chin, L., Chiu, M. I., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1595 · Cited by 83
Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
Shaurova, T., Zhang, L., Goodrich, D. W., & Hershberger, P. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00281 · Cited by 82
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 104
Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations
Yeo, W.-L., Riely, G. J., Yeap, B. Y., Lau, M. W., Warner, J. L., Bodio, K., Huberman, M. S., Kris, M. G., Tenen, D. G., Pao, W. J., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181dd1386 · Cited by 82
Self-citation
Contemporary pre-clinical development of anticancer agents – What are the optimal preclinical models?
Damia, G. L. M., & D’Incalci, M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.08.008 · Cited by 83
Epidermal growth factor receptor (EGFR) involvement in epithelial‐derived cancers and its current antibody‐based immunotherapies
London, M., & Gallo, E. (2020) · Cell Biology International · doi:10.1002/cbin.11340 · Cited by 82
EGFR kinase domain mutations – functional impact and relevance for lung cancer therapy
Irmer, D. J., Funk, J. O., & Blaukat, A. (2007) · Oncogene · doi:10.1038/sj.onc.1210383 · Cited by 83
Epidermal growth factor receptor in relation to tumor development: EGFR‐targeted anticancer therapy
Okamoto, I. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07449.x · Cited by 81
Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the Lung
Soh, J., Toyooka, S., Ichihara, S., Asano, H., Kobayashi, N., Suehisa, H., Otani, H., Yamamoto, H., Ichimura, K., Kiura, K., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168d20a · Cited by 80
The duality of human oncoproteins: drivers of cancer and congenital disorders
Castel, P., Rauen, K. A., & McCormick, F. P. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0256-z · Cited by 80
Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras
Takamochi, K., Oh, S., Matsuoka, J., & Suzuki, K. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.08.007 · Cited by 78
EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance
Jiang, S., Yamashita, K., Yamamoto, M., Chun-ji, P., Umezawa, A., Saegusa, M., Yoshida, T., Katagiri, M., Masuda, N., Hayakawa, K., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23868 · Cited by 75
A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
Felip, E., Rojo, F., Reck, M., Heller, A., Klughammer, B., Sala, G., Cedrés, S., Peralta, S., Maacke, H., Foernzler, D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5186 · Cited by 79
Epidermal growth factor receptor mutations in lung cancers
Yatabe, Y., & Mitsudomi, T. (2007) · Pathology International · doi:10.1111/j.1440-1827.2007.02098.x · Cited by 77
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11881 · Cited by 79
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA
Nakamura, T., Sueoka‐Aragane, N., Iwanaga, K., Sato, A., Komiya, K., Kobayashi, N., Hayashi, S., Hosomi, T., Hirai, M., Sueoka, E., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825f2821 · Cited by 74
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
Riely, G. J. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174e96e · Cited by 74
Current Approaches in NSCLC Targeting K-RAS and EGFR
Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74
Genetic and epigenetic changes in lung carcinoma and their clinical implications
Wen, J., Fu, J., Zhang, W., & Guo, M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.46 · Cited by 77
Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR -Mutant Cells
Zhang, J., Iwanaga, K., Choi, K. C., Wislez, M., Raso, M. G., Wei, W., Wistuba, I. I., & Kurie, J. M. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0014 · Cited by 74
Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma
Huang, Q., Schneeberger, V. E., Luetteke, N., Jin, C., Afzal, R., Budzevich, M. M., Makanji, R. J., Martinez, G. V., Shen, T., Zhao, L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0258 · Cited by 72
Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation
Bollu, L. R., Katreddy, R. R., Blessing, A. M., Pham, N., Zheng, B., Wu, X., & Weihua, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.5252 · Cited by 71
Lineage factors and differentiation states in lung cancer progression
Cheung, W. K. C., & Nguyen, D. X. (2015) · Oncogene · doi:10.1038/onc.2015.85 · Cited by 71
Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinomaPreprint
Li, C. M.-C., Chen, G., Dayton, T. L., Kim-Kiselak, C., Hoersch, S., Whittaker, C. A., Bronson, R. T., Beer, D. G., Winslow, M. M., & Jacks, T. (2013) · Genes & Development · doi:10.1101/gad.222745.113 · Cited by 71
The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors
Schneider, M. R., & Yarden, Y. (2015) · Oncogene · doi:10.1038/onc.2015.372 · Cited by 69
Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3–CD8+ T cells
Deng, S., Sun, Z., Qiao, J., Liang, Y., Liu, L., Dong, C., Shen, A., Wang, Y., Tang, H., Fu, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132000 · Cited by 67
EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82
Yang, C.-H., Chou, H.-C., Fu, Y.-N., Yeh, C.-L., Cheng, H.-W., Chang, I., Liu, K., Chang, G., Tsai, T., Tsai, S., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.04.020 · Cited by 67
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor–Driven Lung Adenocarcinoma
Maity, T. K., Venugopalan, A., Linnoila, I., Cultraro, C. M., Giannakou, A., Nemati, R., Zhang, X., Webster, J. D., Ritt, D., Ghosal, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0750 · Cited by 73
Self-citation
MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression
Pan, D., Jiang, C., Ma, Z., Blonska, M., You, M. J., & Lin, X. (2015) · Oncogene · doi:10.1038/onc.2015.146 · Cited by 67
Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells
Forloni, M., Gupta, R., Nagarajan, A. G., Sun, L., Dong, Y., Pirazzoli, V., Toki, M. I., Wurtz, A., Melnick, M. A., Kobayashi, S. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.087 · Cited by 66
Self-citation
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 68
ErbBs in lung cancer
Sharma, S. V., & Settleman, J. E. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.026 · Cited by 67
Review of the current targeted therapies for non-small-cell lung cancer
Nguyen, K.-S. H. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.576 · Cited by 62
Gprc5a Deletion Enhances the Transformed Phenotype in Normal and Malignant Lung Epithelial Cells by Eliciting Persistent Stat3 Signaling Induced by Autocrine Leukemia Inhibitory Factor
Chen, Y., Deng, J., Fujimoto, J., Kadara, H. N., Men, T., Lotan, D., & Lotan, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0518 · Cited by 66
Efficacy of a Cancer Vaccine against ALK -Rearranged Lung Tumors
Voena, C., Menotti, M., Mastini, C., Giacomo, F. D., Longo, D. L., Castella, B., Merlo, M. E. B., Ambrogio, C., Wang, Q., Minero, V. G., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0089 · Cited by 64
Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy
Biktasova, A. K., Dudimah, D. F., Uzhachenko, R. V., Park, K., Akhter, A., Arasada, R. R., Evans, J. V., Novitskiy, S. V., Tchekneva, E. E., Carbone, D. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1154 · Cited by 59
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
Starrett, J. H., Guernet, A. A., Cuomo, M. E., Poels, K. E., van Rosenburgh, I. K. V. A., Nagelberg, A. L., Farnsworth, D., Price, K. S., Khan, H., Ashtekar, K. D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3819 · Cited by 62
Self-citation
Lung cancer stem cells: Molecular features and therapeutic targets
Singh, S., & Chellappan, S. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.08.003 · Cited by 57
The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants
Chung, B., Dimri, M., George, M. E., Reddi, A. L., Chen, G.-S., Band, V., & Band, H. (2009) · Oncogene · doi:10.1038/onc.2009.31 · Cited by 62
Isolation of Epithelial, Endothelial, and Immune Cells from Lungs of Transgenic Mice with Oncogene-Induced Lung Adenocarcinomas
Bantikassegn, A., Song, X., & Politi, K. A. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0312ma · Cited by 57
Self-citation
Minimal residual disease in cancer therapy – Small things make all the difference
Blatter, S., & Rottenberg, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.003 · Cited by 55
Api6/AIM/Spα/CD5L Overexpression in Alveolar Type II Epithelial Cells Induces Spontaneous Lung Adenocarcinoma
Li, Y., Qu, P., Wu, L., Li, B., Du, H., & Yan, C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4225 · Cited by 56
Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories
Hynds, R. E., Frese, K. K., Pearce, D. R., Gronroos, E. C., Dive, C., & Swanton, C. (2021) · Open Biology · doi:10.1098/rsob.200247 · Cited by 59
ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis
Martinengo, C., Poggio, T., Menotti, M., Scalzo, M. S., Mastini, C., Ambrogio, C., Pellegrino, E., Riera, L., Piva, R., Ribatti, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0268 · Cited by 55
Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update
Ahsan, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_7 · Cited by 56
Genetically-engineered mouse models of small cell lung cancer: the next generation
Oser, M. G., MacPherson, D. P., Oliver, T. G., Sage, J., & Park, K.-S. (2024) · Oncogene · doi:10.1038/s41388-023-02929-7 · Cited by 54
TERTPolymorphism rs2736100-C Is Associated with EGFR Mutation–Positive Non–Small Cell Lung Cancer
Wei, R., Cao, L., Pu, H., Wang, H., Zheng, Y., Niu, X., Weng, X., Zhang, H., Favus, M. J., Zhang, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0009 · Cited by 54
Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas
Li, D., Ji, H., Zaghlul, S., McNamara, K. L., Liang, M., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30446 · Cited by 53
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Neal, J. W., & Nguyen, K.-S. H. (2012) · Biologics · doi:10.2147/btt.s26558 · Cited by 53
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response
Zhang, X., Maity, T. K., Kashyap, M. K., Bansal, M., Venugopalan, A. K., Singh, S., Awasthi, S., Marimuthu, A., Jacob, H. K. C., Belkina, N., et al. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m117.067439 · Cited by 50
CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer
Ali, A., Levantini, E., Fhu, C. W., Teo, J. T., Clohessy, J. G., Goggi, J., Wu, C.-S., Chen, L., Chin, T. M., & Tenen, D. G. (2019) · Theranostics · doi:10.7150/thno.35805 · Cited by 52
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Hobor, S., Bakir, M. A., Hiley, C. T., Skrzypski, M. T., Frankell, A. M., Bakker, B., Watkins, T. B. K., Markovets, A. A., Dry, J. R., Brown, A. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47606-9 · Cited by 51
NCI's provocative questions on cancer: some answers to ignite discussion
Blagosklonny, M. V. (2011) · Oncotarget · doi:10.18632/oncotarget.432 · Cited by 51
Fer Protein-Tyrosine Kinase Promotes Lung Adenocarcinoma Cell Invasion and Tumor Metastasis
Ahn, J., Truesdell, P. F., Meens, J., Kadish, C., Yang, X., Boag, A. H., & Craig, A. W. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0003-t · Cited by 51
Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages
Wang, D.-H., Lee, H., Yoon, D. K., Berry, G. J., Wheeler, T. M., Sugarbaker, D. J., Kheradmand, F., Engleman, E. G., & Burt, B. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2597 · Cited by 50
Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung
Suehisa, H., Toyooka, S., Hotta, K., Uchida, A., Soh, J., Fujiwara, Y., Matsuo, K., Ouchida, M., Takata, M., Kiura, K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8646 · Cited by 51
EGFR is required for FOS‐dependent bone tumor development via RSK2/CREB signaling
Linder, M., Glitzner, E., Srivatsa, S., Bakiri, L., Matsuoka, K., Shahrouzi, P., Dumanic, M., Novoszel, P., Mohr, T. T., Langer, O., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809408 · Cited by 51
EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans
Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.014 · Cited by 51
Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
Johnson, J. L., Pillai, S., & Chellappan, S. (2012) · Biochemistry Research International · doi:10.1155/2012/940405 · Cited by 52
Progress and applications of mouse models for human lung cancer
Seranno, S. D., & Meuwissen, R. L. J. (2010) · European Respiratory Journal · doi:10.1183/09031936.00124709 · Cited by 50
The Molecular Genetics of Lung Cancer
Shames, D. S., Sato, M., & Minna, J. D. (2008) · Lung Cancer · doi:10.1002/9780470696330.ch4 · Cited by 50
IL-33 increases ST2+Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner
Halvorsen, E. C., Franks, S. E., Wadsworth, B. J., Harbourne, B., Cederberg, R. A., Steer, C. A., Martínez-González, I., Calder, J., Lockwood, W. W., & Bennewith, K. L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1527497 · Cited by 51
Stearoyl-CoA Desaturase-1 dependent lipid droplets accumulation in cancer-associated fibroblasts facilitates the progression of lung cancer
Zhang, Y., Gu, Z., Wan, J., Lou, X., Liu, S., Wang, Y., Bian, Y., Wang, F., Li, Z., & Qin, Z. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.74924 · Cited by 48
Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma
Schneeberger, V. E., Ren, Y., Luetteke, N., Huang, Q., Chen, L., Lawrence, H. R., Lawrence, N. J., Haura, E. B., Koomen, J. M., Coppola, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3356 · Cited by 49
Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib‐resistance in cells carrying EGFR mutation
Uchida, A., Hirano, S., Kitao, H., Ogino, A., Rai, K., Toyooka, S., Takigawa, N., Tabata, M., Takata, M., Kiura, K., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00387.x · Cited by 47
Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies
Dominguez, C. L., Tsang, K.-Y., & Palena, C. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.297 · Cited by 47
Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib
Shochet, G. E., Brook, E., Eyal, O., Edelstein, E., & Shitrit, D. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00526.2018 · Cited by 47
HIF‐1α is necessary for activation and tumour‐promotion effect of cancer‐associated fibroblasts in lung cancer
Zhang, Y., Bian, Y., Wang, Y., Wang, Y., Duan, X., Han, Y., Zhang, L., Wang, F., Gu, Z., & Qin, Z. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16556 · Cited by 47
Targeting ADAMS and ERBBs in lung cancer
Hynes, N. E., & Schlange, T. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.012 · Cited by 47
The use of GEM models for experimental cancer therapeutics
Gopinathan, A., & Tuveson, D. A. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000570 · Cited by 47
Capturing cancer evolution using genetically engineered mouse models (GEMMs)
Hill, W., Caswell, D. R., & Swanton, C. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.07.003 · Cited by 47
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma
Pirazzoli, V., Ayeni, D. O., Meador, C. B., Sanganahalli, B. G., Hyder, F., de Stanchina, E., Goldberg, S. B., Pao, W. J., & Politi, K. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0620 · Cited by 46
Self-citation
Effector mechanisms of therapeutic antibodies against ErbB receptors
Peipp, M., Dechant, M., & Valerius, T. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.012 · Cited by 48
A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression
Tang, Z., Hu, J. S., Li, X.-C., Wang, W. J., Zhang, H.-Y., Guo, Y., Shuai, X., Chu, Q., Xie, C., Lin, D., et al. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.10.010 · Cited by 46
Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule
Nakano, H., Soda, H., Takasu, M., Tomonaga, N., Yamaguchi, H., Nakatomi, K., Fujino, S., Hayashi, T., Nakamura, Y., Tsukamoto, K., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.08.021 · Cited by 44
SHP2E76K mutant promotes lung tumorigenesis in transgenic mice
Schneeberger, V. E., Luetteke, N., Ren, Y., Berns, H., Chen, L., Foroutan, P., Martinez, G. V., Haura, E. B., Chen, J., Coppola, D., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu025 · Cited by 44
DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
Berger, A. H., Chen, M., Morotti, A., Janas, J. A., Niki, M., Bronson, R. T., Taylor, B. S., Ladanyi, M., Aelst, L. V., Politi, K. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079526 · Cited by 43
Self-citation
Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
Hu, J., Zhang, H., Cao, M., Wang, L., Wu, S., & Fang, B. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1173 · Cited by 46

Authors: Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Politi, Katerina
Zakowski, Maureen F.
Fan, Pang-Dian
Schonfeld, Emily A.
Pao, William
Varmus, Harold E.
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 2006-05-16
Volume: 20
Issue: 11
Pages: 1496-1510
ISSN: 0890-9369 (ISSN-L)
1549-5477
DOI: 10.1101/gad.1417406
OpenAlex: W2126181231
Cited by: 478
References: 50
Citations by year: 2026: 10 · 2025: 14 · 2024: 18 · 2023: 23 · 2022: 15 · 2021: 17 · 2020: 15 · 2019: 9 · 2018: 24 · 2017: 11 · 2016: 23 · 2015: 38 · 2014: 25 · 2013: 19 · 2012: 27
Type: posted content
Language: en
Open access: bronze
doi.org
Locations: Genes & Development (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed (publishedVersion)
Funders: Memorial Sloan-Kettering Cancer Center
Dana-Farber Cancer Institute
University of Cincinnati
National Institutes of Health (R24 CA83084)
Genentech
National Cancer Institute (K08CA097980, R24CA083084)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: lung adenocarcinoma, epidermal growth factor receptor, EGFR mutation, exon 19 deletion, L858R mutation, tyrosine kinase inhibitors, erlotinib, gefitinib, transgenic mouse model, alveolar type II cells, tumor regression, tumor maintenance, doxycycline-inducible expression, bronchioloalveolar carcinoma
MeSH terms: Adenocarcinoma, Animals, Base Sequence, Humans, Lung Neoplasms, Magnetic Resonance Imaging, Phosphorylation, Protein-Tyrosine Kinases, Down-Regulation, DNA Primers, Mice, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks